Tailored Lipid Nanoparticle Delivery Systems for Animal Health

DIVERSA Technologies develops proprietary lipid nanoparticle delivery systems tailored to meet the needs of the animal health sector. Our platforms enable precise, efficient delivery of a wide range of veterinary actives, including mRNA, siRNA, DNA, monoclonal antibodies, proteins, peptides, small molecules, and natural extracts.

With >90% encapsulation efficiency, our LNPs enhance therapeutic impact while maintaining safety profiles validated in multiple in vivo models. We’ve demonstrated up to 28X higher in vitro and 567X higher in vivo delivery efficiency, along with a >26-fold increase in half-life, reducing dosing frequency and improving treatment outcomes for animals.

Key benefits for veterinary applications include:

• Scalability: Smooth progression from lab-scale to industrial production for commercial deployment.

• Precision targeting: Directs actives to specific organs or tissues, improving efficacy and minimizing systemic exposure.

• Improved bioavailability: Enhances uptake and ensures sustained activity, critical for veterinary treatments.

• Stabilization: Protects sensitive molecules under biological and storage conditions.

• Versatility: Delivers diverse actives, from nucleic acids to complex biologics and small molecules.

• PEG-free options: We offer PEG-free formulations to address regulatory or immunogenicity concerns, expanding compatibility and safety.

By leveraging our patented platforms and extensive formulation expertise, DIVERSA helps accelerate the development of innovative veterinary products, supporting predictive and preventive animal health strategies with clear IP and freedom-to-operate (FTO).